Provided by Tiger Fintech (Singapore) Pte. Ltd.

Rhythm Pharmaceuticals Inc.

64.01
+0.21000.33%
Post-market: 64.010.00000.00%17:34 EDT
Volume:475.18K
Turnover:30.74M
Market Cap:4.07B
PE:-14.76
High:66.09
Open:64.06
Low:63.89
Close:63.80
Loading ...

Rhythm Pharmaceuticals:Setmelanotide in Global Phase 3 Trial for Acquired Hypothalamic Obesity, With Topline Data on Track to Be Disclosed in Q2 2025

THOMSON REUTERS
·
20 Mar

Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan

GlobeNewswire
·
20 Mar

Citizens JMP pharmaceuticals analysts hold analyst/industry conference call

TIPRANKS
·
19 Mar

Rhythm Pharmaceuticals Is Maintained at Buy by Needham

Dow Jones
·
18 Mar

Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration

GlobeNewswire
·
18 Mar

Stifel Nicolaus Sticks to Its Buy Rating for Rhythm Pharmaceuticals (RYTM)

TIPRANKS
·
11 Mar

Rhythm Pharmaceuticals Coverage Assumed by Morgan Stanley at Overweight

Dow Jones
·
08 Mar

Promising Outlook for Rhythm Pharmaceuticals: Buy Rating Backed by Positive Phase 3 Study Expectations and Market Potential

TIPRANKS
·
07 Mar

Rhythm Pharmaceuticals Price Target Announced at $78.00/Share by Stifel

Dow Jones
·
06 Mar

Rhythm Pharmaceuticals Inc : Stifel Resumes Coverage With Buy Rating; Price Target $78

THOMSON REUTERS
·
05 Mar

US High Growth Tech Stocks to Watch in March 2025

Simply Wall St.
·
05 Mar

Rhythm Pharmaceuticals Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line

Simply Wall St.
·
03 Mar

Rhythm Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
03 Mar

Rhythm Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $70 From $69

THOMSON REUTERS
·
03 Mar

Rhythm Pharmaceuticals Faces Financial Risks Due to Convertible Preferred Stock Prioritization

TIPRANKS
·
01 Mar

Rhythm Pharmaceuticals Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
28 Feb

We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Can Afford To Drive Business Growth

Simply Wall St.
·
27 Feb

Rhythm Pharmaceuticals Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line

Simply Wall St.
·
27 Feb

Rhythm Pharmaceuticals Inc (RYTM) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

GuruFocus.com
·
27 Feb

Q4 2024 Rhythm Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents
·
27 Feb